Showing results (161-170 of 175) with videos related to
Sort By:
Pageof 18
The Journal of Steroid Biochemistry and Molecular Biology|February 4, 1998
Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptorsT E Johnson, M K Holloway, R Vogel, et al.The EMBO Journal|March 1, 1994
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletionV Poli, R Balena, E Fattori, et al.Journal of Periodontal Research|January 1, 1994
Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeysM Weinreb, H Quartuccio, J G Seedor, et al.Bioorganic & Medicinal Chemistry|July 10, 1999
Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosisL Gil, Y Han, E E Opas, et al.The Journal of Clinical Investigation|May 1, 1995
Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year studyM H Lafage, R Balena, M A Battle, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 27, 2004
Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to manT Prueksaritanont, C Fernandez-Metzler, Y Meng, et al.Journal of Cell Science|November 5, 1999
Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zoneI Nakamura, M F Pilkington, P T Lakkakorpi, et al.Endocrinology|March 1, 1993
Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing proteinJ E Fisher, M P Caulfield, M Sato, et al.Journal of Medicinal Chemistry|January 5, 2001
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and LJ P Falgueyret, R M Oballa, O Okamoto, et al.Bone|December 20, 2005
Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCTL D Hordon, M Itoda, P A Shore, et al.Pageof 18